arrow_back Back to App

Increasing Access to Biosimilar Drugs in Medicare Program

This act aims to increase the availability of more affordable biosimilar drugs for individuals covered by Medicare. It establishes a pilot program to encourage healthcare providers to use these drugs more frequently, potentially lowering treatment costs for patients and the healthcare system.
Key points
Pilot Program: A 3-year program will be established to evaluate the benefits of additional payments to providers for using biosimilar drugs.
No Increased Patient Costs: Additional payments to providers will not increase Medicare beneficiaries' out-of-pocket costs.
Voluntary Participation: Provider participation in the program is voluntary, and they can withdraw at any time.
Reports to Congress: The Secretary of Health and Human Services will regularly report to Congress on the program's results, potentially leading to its expansion.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_2869
Sponsor: Rep. Cárdenas, Tony [D-CA-29]
Process start date: 2021-04-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Increasing Access to Biosimilars Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_2869.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • Pilot Program: A 3-year program will be established to evaluate the benefits of additional payments to providers for using biosimilar drugs.
  • No Increased Patient Costs: Additional payments to providers will not increase Medicare beneficiaries' out-of-pocket costs.
  • Voluntary Participation: Provider participation in the program is voluntary, and they can withdraw at any time.
  • Reports to Congress: The Secretary of Health and Human Services will regularly report to Congress on the program's results, potentially leading to its expansion.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Cárdenas, Tony [D-CA-29].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health